Multiple Sclerosis Clinical Trial

Evaluation of Natalizumab for thE Relief of MS Associated FatiGue

Summary

This study aims to study the effects of TYSABRI® treatment on fatigue and cognition in patients with relapsing forms of MS.

View Full Description

Full Description

TYSABRI® treatment has already demonstrated significant improvement in the quality of life (QoL) of patients with MS. In particular, TYSABRI® add-on treatment to interferon beta-1a has demonstrated improvement in fatigue as measured by the Modified Fatigue Impact Scale (MFIS). Both patients and neurologists report that patients have experienced significant improvements in fatigue shortly after initiating TYSABRI® treatment. Fatigue is both a common and a disabling symptom of MS. Further, there is evidence that fatigue contributes to cognitive difficulties in patients with MS. This study aims to study the effects of TYSABRI® treatment on fatigue and cognition in patients with relapsing forms of MS.

The primary objective of this study is to determine the effects of TYSABRI® treatment on fatigue in subjects with relapsing forms of MS as measured by changes in patient-reported Visual Analog Scale for Fatigue (VAS-F).

Primary endpoint is the change in the following:

1. Visual Analog Scale for Fatigue (VAS-F) at three months after initiating treatment with TYSABRI®.

Secondary objectives are to measure changes in patient-reported Modified Fatigue Impact Scale (MFIS) and Fatigue Severity Scale (FSS).

Secondary endpoints are changes in the following:

Modified Fatigue Impact Scale (MFIS)
Fatigue Severity Scale (FSS)

The tertiary objective of this study is to explore for any effects of TYSABRI® treatment on cognition by assessing changes in the Automated Neuropsychology Assessment Metrics (ANAM).

Tertiary endpoints are changes in the Automated Neuropsychology Assessment Metrics (ANAM) consisting of:

Traditional Continuous Performance Test
Running Memory Continuous Performance Test
Simple Response Time
Procedural Response Time
Coding Substitution
Mathematics
Logical Relations
Matching-to-Sample
Stanford Sleepiness Scale

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Diagnosis of relapsing forms of MS.
Patients having an inadequate response to or unable to tolerate alternate MS therapies.
Patient must be enrolled in the TOUCH prescribing program.
Recent MRI as part of the TOUCH prescribing program.
Patient must be between 18 and 55 years of age, inclusive.
EDSS between 0 and 5.5, inclusive.
Able to provide written informed consent.
Capable of completing the fatigue (MFIS, FSS, and VAS-F) and cognition (ANAM) sessions.
A baseline VAS-F average score of > 60.
Patient must be naÃ-ve to TYSABRI® treatment.

Exclusion Criteria:

Patients not enrolled in the TOUCH prescribing program.
History or presence of progressive multifocal leukoencephalopathy (PML).
Diagnosis of primary progressive MS (PPMS) or secondary progressive MS (SPMS) without relapses.
Immunocompromised in the judgment of the investigator.
Allergy or hypersensitivity to TYSABRI®.
Prior history or current presence of a clinically significant medical illness or laboratory abnormality, including any significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric, renal, and/or other major disease, that, in the opinion of the investigator, would preclude the administration of TYSABRI®.
Women pregnant, breast feeding, or planning to become pregnant and women who are not postmenopausal or surgically sterile, and unwilling to practice contraception.
A baseline average VAS-F score of < 60.
Problems with upper extremity dexterity that could preclude usage of a computer mouse.
With educational completion below 8th grade school equivalent or non-fluent in English.
Any other reason, in the opinion of both the Investigator and/or Sponsor, the patient is determined not suitable for study participation.

Study is for people with:

Multiple Sclerosis

Estimated Enrollment:

89

Study ID:

NCT00464074

Recruitment Status:

Completed

Sponsor:

Biogen

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 31 Locations for this study

See Locations Near You

Research Site
Phoenix Arizona, 85006, United States
Research Site
Fresno California, 93720, United States
Research Site
Atlanta Georgia, 30327, United States
Research Site
Idaho Falls Idaho, 83404, United States
Research Site
Evanston Illinois, 60201, United States
Research Site
Lake Barrington Illinois, 60010, United States
Research Site
Indianapolis Indiana, 46256, United States
Research Site
West Des Moines Iowa, 50314, United States
Research Site
Lexington Kentucky, 40503, United States
Research Site
Louisville Kentucky, 40202, United States
Research Site
Boston Massachusetts, 02135, United States
Research Site
Lexington Massachusetts, 02421, United States
Research Site
Farmington Hills Michigan, 48334, United States
Research Site
Buffalo New York, 14203, United States
Research Site
New York New York, 10003, United States
Research Site
Patchogue New York, 11772, United States
Research Site
Chapel Hill North Carolina, 27599, United States
Research Site
High Point North Carolina, 27262, United States
Research Site
Raleigh North Carolina, 27607, United States
Research Site
Portland Oregon, 97225, United States
Research Site
Anderson South Carolina, 29621, United States
Research Site
Franklin Tennessee, 37064, United States
Research Site
Knoxville Tennessee, 37934, United States
Research Site
Nashville Tennessee, 37205, United States
Research Site
Nashville Tennessee, 37212, United States
Research Site
Salt Lake City Utah, 84103, United States
Research Site
Salt Lake City Utah, 84108, United States
Research Site
Seattle Washington, 98195, United States
Research Site
Charleston West Virginia, 25301, United States
Research Site
Waukesha Wisconsin, 53188, United States
Research Site
Guaynabo , 00969, Puerto Rico

How clear is this clinincal trial information?

Study is for people with:

Multiple Sclerosis

Estimated Enrollment:

89

Study ID:

NCT00464074

Recruitment Status:

Completed

Sponsor:


Biogen

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.